Cepharanthine suppresses osteoclast formation by modulating the nuclear factor-κB and nuclear factor of activated T-cell signaling pathways

Xixi Lin, Fangming Song, Lin Zhou, Ziyi Wang, Chengming Wei, Jiake Xu, Jinmin Zhao, Qian Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The increased activation of osteoclasts is the major manifestation of several lytic bone diseases, including osteoporosis, rheumatoid arthritis, aseptic loosening of orthopedic implants, Paget disease and malignant bone diseases. One important bone-protective therapy in these diseases focuses on the inhibition of osteoclast differentiation and resorptive function. Given that the deleterious side-effects of currently available drugs, it is beneficial to search for effective and safe medications from natural compounds. Cepharanthine (CEP) is a compound extracted from Stephania japonica and has been found to have antioxidant and anti-inflammatory effects. In this study, we found that CEP inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclast formation and bone-resorbing activities using osteoclastogenesis and bone resorption assay. By polymerase chain reaction, we also found that CEP inhibited the expression of osteoclast-differentiation marker genes including Ctsk, Calcr, Atp6v0d2, Mmp9 and Nfatc1. Mechanistic analyses including Western blot and luciferase reporter assay revealed that CEP inhibited RANKL-induced activation of NF-κB and nuclear factor of activated T-cell, which are essential for the formation of osteoclast. Collectively, these data suggested that CEP can potentially be used as an alternative therapy for preventing or treating osteolytic diseases.

Original languageEnglish
Pages (from-to)1990-1996
Number of pages7
JournalJournal of Cellular Biochemistry
Volume120
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

NFATC Transcription Factors
Cell signaling
Osteoclasts
Bone
Bone Diseases
Assays
Stephania
Chemical activation
Osteitis Deformans
Polymerase chain reaction
Differentiation Antigens
Orthopedics
Bone Resorption
Cytoplasmic and Nuclear Receptors
Complementary Therapies
Luciferases
Osteogenesis
Osteoporosis
Rheumatoid Arthritis
Anti-Inflammatory Agents

Cite this

Lin, Xixi ; Song, Fangming ; Zhou, Lin ; Wang, Ziyi ; Wei, Chengming ; Xu, Jiake ; Zhao, Jinmin ; Liu, Qian. / Cepharanthine suppresses osteoclast formation by modulating the nuclear factor-κB and nuclear factor of activated T-cell signaling pathways. In: Journal of Cellular Biochemistry. 2019 ; Vol. 120, No. 2. pp. 1990-1996.
@article{d4e1a89744234508baf63b85320b8760,
title = "Cepharanthine suppresses osteoclast formation by modulating the nuclear factor-κB and nuclear factor of activated T-cell signaling pathways",
abstract = "The increased activation of osteoclasts is the major manifestation of several lytic bone diseases, including osteoporosis, rheumatoid arthritis, aseptic loosening of orthopedic implants, Paget disease and malignant bone diseases. One important bone-protective therapy in these diseases focuses on the inhibition of osteoclast differentiation and resorptive function. Given that the deleterious side-effects of currently available drugs, it is beneficial to search for effective and safe medications from natural compounds. Cepharanthine (CEP) is a compound extracted from Stephania japonica and has been found to have antioxidant and anti-inflammatory effects. In this study, we found that CEP inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclast formation and bone-resorbing activities using osteoclastogenesis and bone resorption assay. By polymerase chain reaction, we also found that CEP inhibited the expression of osteoclast-differentiation marker genes including Ctsk, Calcr, Atp6v0d2, Mmp9 and Nfatc1. Mechanistic analyses including Western blot and luciferase reporter assay revealed that CEP inhibited RANKL-induced activation of NF-κB and nuclear factor of activated T-cell, which are essential for the formation of osteoclast. Collectively, these data suggested that CEP can potentially be used as an alternative therapy for preventing or treating osteolytic diseases.",
keywords = "cepharanthine, nuclear factor of activated T-cell, nuclear factor-κB, osteoclast, receptor activator of nuclear factor-κB ligand",
author = "Xixi Lin and Fangming Song and Lin Zhou and Ziyi Wang and Chengming Wei and Jiake Xu and Jinmin Zhao and Qian Liu",
year = "2019",
month = "2",
day = "1",
doi = "10.1002/jcb.27495",
language = "English",
volume = "120",
pages = "1990--1996",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss",
number = "2",

}

Cepharanthine suppresses osteoclast formation by modulating the nuclear factor-κB and nuclear factor of activated T-cell signaling pathways. / Lin, Xixi; Song, Fangming; Zhou, Lin; Wang, Ziyi; Wei, Chengming; Xu, Jiake; Zhao, Jinmin; Liu, Qian.

In: Journal of Cellular Biochemistry, Vol. 120, No. 2, 01.02.2019, p. 1990-1996.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cepharanthine suppresses osteoclast formation by modulating the nuclear factor-κB and nuclear factor of activated T-cell signaling pathways

AU - Lin, Xixi

AU - Song, Fangming

AU - Zhou, Lin

AU - Wang, Ziyi

AU - Wei, Chengming

AU - Xu, Jiake

AU - Zhao, Jinmin

AU - Liu, Qian

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The increased activation of osteoclasts is the major manifestation of several lytic bone diseases, including osteoporosis, rheumatoid arthritis, aseptic loosening of orthopedic implants, Paget disease and malignant bone diseases. One important bone-protective therapy in these diseases focuses on the inhibition of osteoclast differentiation and resorptive function. Given that the deleterious side-effects of currently available drugs, it is beneficial to search for effective and safe medications from natural compounds. Cepharanthine (CEP) is a compound extracted from Stephania japonica and has been found to have antioxidant and anti-inflammatory effects. In this study, we found that CEP inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclast formation and bone-resorbing activities using osteoclastogenesis and bone resorption assay. By polymerase chain reaction, we also found that CEP inhibited the expression of osteoclast-differentiation marker genes including Ctsk, Calcr, Atp6v0d2, Mmp9 and Nfatc1. Mechanistic analyses including Western blot and luciferase reporter assay revealed that CEP inhibited RANKL-induced activation of NF-κB and nuclear factor of activated T-cell, which are essential for the formation of osteoclast. Collectively, these data suggested that CEP can potentially be used as an alternative therapy for preventing or treating osteolytic diseases.

AB - The increased activation of osteoclasts is the major manifestation of several lytic bone diseases, including osteoporosis, rheumatoid arthritis, aseptic loosening of orthopedic implants, Paget disease and malignant bone diseases. One important bone-protective therapy in these diseases focuses on the inhibition of osteoclast differentiation and resorptive function. Given that the deleterious side-effects of currently available drugs, it is beneficial to search for effective and safe medications from natural compounds. Cepharanthine (CEP) is a compound extracted from Stephania japonica and has been found to have antioxidant and anti-inflammatory effects. In this study, we found that CEP inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclast formation and bone-resorbing activities using osteoclastogenesis and bone resorption assay. By polymerase chain reaction, we also found that CEP inhibited the expression of osteoclast-differentiation marker genes including Ctsk, Calcr, Atp6v0d2, Mmp9 and Nfatc1. Mechanistic analyses including Western blot and luciferase reporter assay revealed that CEP inhibited RANKL-induced activation of NF-κB and nuclear factor of activated T-cell, which are essential for the formation of osteoclast. Collectively, these data suggested that CEP can potentially be used as an alternative therapy for preventing or treating osteolytic diseases.

KW - cepharanthine

KW - nuclear factor of activated T-cell

KW - nuclear factor-κB

KW - osteoclast

KW - receptor activator of nuclear factor-κB ligand

UR - http://www.scopus.com/inward/record.url?scp=85056446659&partnerID=8YFLogxK

U2 - 10.1002/jcb.27495

DO - 10.1002/jcb.27495

M3 - Article

VL - 120

SP - 1990

EP - 1996

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 2

ER -